If you're Black and sick, the deck is stacked against you for many reasons | Opinion
Research has shown that patients who share race and ethnicity with their medical providers have better outcomes, but often ...
PharmiWeb5d
Strong real-world efficacy and safety data with Pepaxti published in the European Journal of Haematology
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...
Cancer screening added to annual physical exams for Fayetteville firefighters. Here's why
The city of Fayetteville has introduced "The One Test," which offers a more immediate assessment of a firefighter's risk of ...
The Gazette4d
Iowa maintains fastest-growing cancer rate as survivor numbers grow
With Iowa maintaining the second-highest rate and fastest-growing rate of new cancers nationally, advancements in treatment ...
Sioux City Journal5d
Iowa maintains fastest-growing cancer rate, but more survive
With Iowa maintaining the second-highest and fastest-growing rate of new cancers nationally, according to a 2025 Cancer in ...
'Only a matter of time': Here is why Arizona is at high risk for a measles outbreak
Arizona is similarly at risk for measles because the state has several pockets of extremely low vaccination rates, including ...
The Waterloo-Cedar Falls Courier4d
Iowa maintains fastest-growing new cancer rate nationally, but more people surviving
Produced by the Iowa Cancer Registry, the annual cancer report collects data on all Iowa residents diagnosed with cancer.
KCAU Sioux City on MSN3d
2025 Cancer in Iowa report shines spotlight on cancer survivors and their needs
The Iowa Cancer Registry released the 2025 Cancer in Iowa report Tuesday, focused on the changing metrics of cancer ...
pharmaphorum3d
Sanofi builds case for Sarclisa, challenging J&J’s Darzalex
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...